Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance

25 Jun 2015

Abstract excerpt

Trastuzumab has been successfully employed for the treatment of Her-2-positive gastric cancer. However, there are problems with both primary and secondary resistance to trastuzumab. In this study, we employed the human gastric carcinoma cell line NCI-N87 with high Her-2 expression to create trastuzumab-resistant NCI-N87/TR cells by stepwise exposure to increasing doses of trastuzumab. Western blotting and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26108989
DOI: 10.1038/srep11634

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistancePMID 26108989Read ↗

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerSemantic proximity Read ↗

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancerSemantic proximity Read ↗

Generation and characterization of a paclitaxel-resistant human gastric carcinoma cell line.Semantic proximity Read ↗

PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.Semantic proximity Read ↗

Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cellsSemantic proximity Read ↗

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity Read ↗

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read ↗

Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.Semantic proximity Read ↗

PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.Semantic proximity Read ↗

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].Semantic proximity Read ↗

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab ResistanceSemantic proximity Read ↗

HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.